Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Ulcerative Colitis

Ulcerative Colitis

Part of Inflammatory Bowel Disease

30 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Ulcerative Colitis

188 trials tracked for Ulcerative Colitis: 76 in phase 3 or 4 and 46 with published results. The most-cited published study has 721 citations.

188Trials tracked
76Phase 3 & 4
0Recruiting
46With published results
Phase distribution
Phase 4 13 Phase 3 63 Phase 2 64 Phase 1 10 Other / NA 38
  1. Phase 3 An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis Completed · 721 cited
  2. Phase 3 Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis Completed · 314 cited
  3. Phase 3 Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis Completed · 223 cited
  4. Phase 3 An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease Completed · 190 cited
  5. Phase 4 Predicting Response to Standardized Pediatric Colitis Therapy Completed · 164 cited
  6. Phase 3 Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1) Completed · 131 cited
Show 44 more trials
  1. Phase 3 Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis Completed · 117 cited
  2. Phase 3 A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis Completed · 116 cited
  3. Phase 3 A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis Completed · 116 cited
  4. Phase 3 A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis Completed · 116 cited
  5. Phase 3 Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis Completed · 99 cited
  6. Phase 3 A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors Completed · 93 cited
  7. Phase 3 A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors Completed · 92 cited
  8. Phase 3 A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors Completed · 87 cited
  9. Phase 3 A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors Completed · 87 cited
  10. Phase 3 A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors Completed · 87 cited
  11. Phase 3 A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis. Completed · 77 cited
  12. Phase 3 Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis Completed · 75 cited
  13. Phase 3 Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA) Completed · 74 cited
  14. Phase 3 Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD) Completed · 61 cited
  15. Phase 3 CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC) Completed · 59 cited
  16. Phase 3 A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting Completed · 44 cited
  17. Phase 3 Effect of Probiotic Supplementation on the Immune System in Patients With Ulcerative Colitis in Amman, Jordan Completed · 41 cited
  18. Phase 3 A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis Completed · 38 cited
  19. Phase 4 Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) Completed · 37 cited
  20. Phase 3 Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis Completed · 33 cited
  21. Phase 4 Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) Completed · 32 cited
  22. Phase 3 The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients Completed · 26 cited
  23. Phase 4 Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis Completed · 25 cited
  24. Phase 4 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate Completed · 24 cited
  25. Phase 4 Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Completed · 23 cited
  26. Phase 3 An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) Completed · 23 cited
  27. Phase 3 Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis Completed · 22 cited
  28. Phase 3 An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis Completed · 22 cited
  29. Phase 3 An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis Completed · 17 cited
  30. Phase 4 Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). Completed · 15 cited
  31. Phase 3 A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease Completed · 12 cited
  32. Phase 4 Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease Completed · 11 cited
  33. Phase 3 Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in Remission Completed · 7 cited
  34. Phase 3 Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis Completed · 6 cited
  35. Phase 3 Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis Completed · 5 cited
  36. Phase 3 Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis Completed · 4 cited
  37. Phase 3 Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis Completed · 4 cited
  38. Phase 3 A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis Completed · 3 cited
  39. Phase 4 Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab Completed · 2 cited
  40. Phase 3 BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis Completed
  41. Phase 4 A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease Completed
  42. Phase 4 Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis Completed
  43. Phase 4 Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC) Completed
  44. Phase 4 Dose Escalation and Remission (DEAR) Completed

Showing the 50 most-cited and recently-updated of 188 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
First Report of Vedolizumab-Associated Recall Urticaria in a Case Report and Literature Review
Allergy & Immunology Sys. Review
First Report of Vedolizumab-Associated Recall Urticaria in a Case Report and Literature Review Why Hives Return to Old Injection Spots
This case report and literature review describes the first documented instance of vedolizumab-associated recall urticaria in a 25-year-old m…
A new case report reveals a rare skin reaction where hives return strictly to past injection sites.
Frontiers Apr 21, 2026
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
Dermatology FDA Approval
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis The FDA approved a drug called Stelara to treat several inflammatory conditions in adults and children
The FDA approved ustekinumab for adult and pediatric patients 6 years and older with moderate to severe plaque psoriasis and active psoriati…
FDA approved Stelara to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in adults an…
FDA Apr 21, 2026
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
Dermatology FDA Approval
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis The FDA has approved a new drug called Stelara for several inflammatory conditions
The FDA approved ustekinumab for adult and pediatric patients 6 years and older with moderate to severe plaque psoriasis and active psoriati…
The FDA has approved Stelara to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in a…
FDA Apr 21, 2026
Narrative review discusses M cell manipulation limitations in inflammatory bowel disease models
Gastroenterology Sys. Review
Narrative review discusses M cell manipulation limitations in inflammatory bowel disease models Can we target gut cells without breaking the whole immune system?
This narrative review addresses challenges in selectively manipulating M cells within traditional animal models and two-dimensional culture …
Scientists are looking for ways to treat Crohn's disease and ulcerative colitis by focusing on specific cells in the gut lining.
Frontiers Apr 20, 2026
Literature review synthesizes Schisandra chinensis effects on gut microbiota and metabolic pathways across multiple conditions
Gastroenterology Sys. Review
Literature review synthesizes Schisandra chinensis effects on gut microbiota and metabolic pathways across multiple conditions This Ancient Berry May Quiet Inflammation From Your Gut to Your Brain
This literature review examines the potential of Schisandra chinensis regarding gut health and metabolic regulation.
An ancient berry used for centuries may rebalance gut bacteria to calm inflammation linked to digestive issues, liver disease, diabetes, and…
Frontiers Apr 19, 2026
AI endoscopic score shows better agreement with ulcerative colitis remission than Mayo score in RCT
Drug Pipeline RCT
AI endoscopic score shows better agreement with ulcerative colitis remission than Mayo score in RCT AI endoscopic scoring shows better agreement with ulcerative colitis symptoms in trial
This phase 3 RCT in 387 subjects with ulcerative colitis compared an AI endoscopic cumulative disease score (CDS) to the Mayo endoscopic sco…
An AI scoring system matched ulcerative colitis symptoms better than standard endoscopy, helping doctors align what they see with how patien…
Apr 19, 2026
Neutrophil SIRL-1/IL-8 Ratio as a Diagnostic Biomarker for Inflammatory Bowel Disease
Neurology Cohort
Neutrophil SIRL-1/IL-8 Ratio as a Diagnostic Biomarker for Inflammatory Bowel Disease New Blood Ratio Could Spot IBD Faster
This single-center cohort study measured neutrophil SIRL-1 and serum IL-8 in 90 IBD patients and healthy volunteers.
A new blood ratio measuring two immune signals could help doctors diagnose Crohn's and Ulcerative Colitis faster and more accurately.
Frontiers Apr 19, 2026
Narrative review examines ulcerative colitis and colorectal cancer risk
Oncology Sys. Review
Narrative review examines ulcerative colitis and colorectal cancer risk Review of ulcerative colitis and colorectal cancer links in patients
This narrative review synthesizes evidence on ulcerative colitis and colorectal cancer risk.
Ulcerative colitis patients face cancer risk driven by inflammation, but better disease control and modern treatments are lowering overall c…
Frontiers Apr 17, 2026
Latent profiles of self-management behavior identified in Chinese ulcerative colitis patients
Primary Care & Family Medicine Cohort
Latent profiles of self-management behavior identified in Chinese ulcerative colitis patients Chinese ulcerative colitis patients show varied self-management behaviors linked to social support and mood
This cross-sectional study of 415 Chinese patients with ulcerative colitis identified three self-management behavior profiles.
Chinese ulcerative colitis patients with strong social support and fewer mood issues actively manage their daily lives better than others.
Frontiers Apr 17, 2026
Cross-sectional data suggest IgG glycans discriminate inflammatory bowel disease from controls
Gastroenterology Cohort
Cross-sectional data suggest IgG glycans discriminate inflammatory bowel disease from controls A Simple Blood Test May Spot Crohn's and Colitis Early
This cross-sectional study analyzed 1,367 plasma samples from individuals with Crohn's disease or ulcerative colitis, healthy controls, and …
A simple blood test reveals a sugar pattern that spots inflammatory bowel disease early and shows how the illness quietly ages the body.
medRxiv Apr 16, 2026
Guselkumab showed improved clinical remission in refractory ulcerative colitis versus placebo
Drug Pipeline RCT
Guselkumab showed improved clinical remission in refractory ulcerative colitis versus placebo Guselkumab shows promise for ulcerative colitis in this early phase 3 trial
This phase 3 randomized trial evaluated guselkumab in adults with moderately to severely active ulcerative colitis who had inadequate respon…
Patients with ulcerative colitis who failed other treatments achieved remission in a new trial using subcutaneous guselkumab injections.
Apr 15, 2026
Meta-analysis finds increased VTE risk in pediatric IBD, especially ulcerative colitis
Pediatrics Meta-analysis
Meta-analysis finds increased VTE risk in pediatric IBD, especially ulcerative colitis Kids with Bowel Disease Face a Hidden Blood Clot Risk Adults Miss
A systematic review and meta-analysis of over 100,000 children and teenagers with IBD found a significantly increased risk of venous thrombo…
Children with Crohn's or ulcerative colitis face nearly seven times the blood clot risk of healthy kids, yet prevention guidelines for teens…
Apr 14, 2026

Questions about Ulcerative Colitis

How does the gut bacteria diversity in ulcerative colitis compare to healthy controls?

Ulcerative colitis patients consistently show reduced gut bacterial diversity (lower Shannon index) and altered composition compared to healthy controls, with depletion of beneficial butyrate-producing bacteria and increases in certain pro-inflammatory groups.

Full answer →
Is there a link between NF-kB pathway inhibition and treating ulcerative colitis?

Yes, inhibiting the NF-κB pathway is a key treatment strategy for ulcerative colitis, as it reduces inflammation and may prevent cancer progression.

Full answer →
Are there specific biomarkers that can accurately diagnose ulcerative colitis in a new patient?

Yes, three biomarkers (ARHGEF3, S100A8, RHOU) show high diagnostic accuracy for ulcerative colitis, and bile acid ratios are also promising noninvasive markers.

Full answer →
Can enteral nutrition therapy help achieve remission in patients with ulcerative colitis?

Enteral nutrition therapy may help achieve remission in ulcerative colitis, with studies showing clinical remission rates around 60% and benefits in acute severe cases, but evidence is stronger for Crohn's disease.

Full answer →